التفاصيل البيبلوغرافية
| العنوان: |
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma |
| المؤلفون: |
Tarhini, Ahmad, McDermott, David, Ambavane, Apoorva, Gupte-Singh, Komal, Aponte-Ribero, Valerie, Ritchings, Corey, Benedict, Agnes, Rao, Sumati, Regan, Meredith M, Atkins, Michael |
| المصدر: |
Immunotherapy ; volume 11, issue 4, page 283-295 ; ISSN 1750-743X 1750-7448 |
| بيانات النشر: |
Informa UK Limited |
| سنة النشر: |
2019 |
| الوصف: |
Aim: The cost–effectiveness of treatment sequences in BRAF-mutant advanced melanoma. Materials & methods: A discrete event simulation model was developed to estimate total costs and health outcomes over a patient's lifetime (30 years). Efficacy was based on the CheckMate 067/069 trials and a matching-adjusted-indirect comparison between immuno-oncology and targeted therapies. Safety, cost (in US dollars; US third-party payer perspective) and health-related quality-of-life inputs were based on published literature. Results: Estimated survival gain was higher for sequences initiating with anti-PD-1 + anti-CTLA-4 than for anti-PD-1 monotherapy or BRAF+MEK inhibitors. The incremental cost–effectiveness ratio per QALY gained for first-line anti-PD-1 + anti-CTLA-4 was US$54,273 versus first-line anti-PD-1 and $79,124 versus first-line BRAF+MEK inhibitors. Conclusion: Initiating treatment with anti-PD-1 + anti-CTLA-4 was more cost–effective than initiation with anti-PD-1 monotherapy or BRAF+MEK inhibitors. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.2217/imt-2018-0168 |
| الإتاحة: |
https://doi.org/10.2217/imt-2018-0168Test |
| رقم الانضمام: |
edsbas.26A0FBD6 |
| قاعدة البيانات: |
BASE |
